Summit Therapeutics opens global Phase II ivonescimab study in kidney cancer
The multiregional study is testing ivonescimab-based regimens in patients who have not had prior treatment for their cancer.
GetSignal Summit Therapeutics Inc. SMMT
Summit Therapeutics said on October 19, 2026 that it has initiated and opened clinical trial sites for a multiregional Phase II study of ivonescimab, an investigational PD-1/VEGF bispecific antibody. The study covers advanced clear cell renal cell carcinoma, the most common form of kidney cancer.
Key facts
- Date announced
- October 19, 2026
- Drug
- Ivonescimab, an investigational PD-1/VEGF bispecific antibody
- Study
- Multiregional Phase II study
- Condition
- Previously untreated advanced clear cell renal cell carcinoma
Source: The company's release on Business Wire, October 19, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
